Literature DB >> 7102701

Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis.

R B Van Dyke, J D Connor, C Wyborny, M Hintz, R E Keeney.   

Abstract

The pharmacokinetics of acyclovir administrated orally in a dose of 200 mg every four hours, five times a day to adults with herpes progenitalis was determined. Peak plasma acyclovir levels are found 1.5 to 1.75 hours after oral administration; peak levels range from 1.4 to 4.0 microM with a mean of 2.5 microM. Acyclovir levels in saliva are well correlated with simultaneous plasma levels, saliva levels being approximately 13 percent of plasma levels. Simultaneous plasma and vaginal secretion acyclovir levels are poorly correlated; peak levels in vaginal secretions range from 0.5 to 3.6 microM.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7102701     DOI： 10.1016/0002-9343(82)90085-7

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


  10 in total

Review 1.  Clinical pharmacokinetics of acyclovir.

Authors:  O L Laskin
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

2.  Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs.

Authors:  M N Ellis; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

3.  Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring.

Authors:  M J Keller; A M Malone; C A Carpenter; Y Lo; M Huang; L Corey; R Willis; C Nguyen; S Kennedy; M Gunawardana; D Guerrero; J A Moss; M M Baum; T J Smith; B C Herold
Journal:  J Antimicrob Chemother       Date:  2012-05-03       Impact factor: 5.790

4.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.

Authors:  Jared M Baeten; Jairam Lingappa; Ingrid Beck; Lisa M Frenkel; Gregory Pepper; Connie Celum; Anna Wald; Kenneth H Fife; Edwin Were; Nelly Mugo; Jorge Sanchez; Myron Essex; Joseph Makhema; James Kiarie; Carey Farquhar; Lawrence Corey
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

5.  Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis.

Authors:  Heather E Vezina; Henry H Balfour; Dennis R Weller; Bruce J Anderson; Richard C Brundage
Journal:  J Clin Pharmacol       Date:  2009-11-06       Impact factor: 3.126

Review 6.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

Review 7.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

Review 8.  Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies.

Authors:  Andrea Ries Thurman; Meredith R Clark; Gustavo F Doncel
Journal:  Infect Dis Obstet Gynecol       Date:  2011-08-09

9.  Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.

Authors:  James M Smith; John A Moss; Priya Srinivasan; Irina Butkyavichene; Manjula Gunawardana; Rob Fanter; Christine S Miller; Debbie Sanchez; Flora Yang; Shanon Ellis; Jining Zhang; Mark A Marzinke; Craig W Hendrix; Amita Kapoor; Marc M Baum
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

Review 10.  Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2.

Authors:  Lauren A Sadowski; Rista Upadhyay; Zachary W Greeley; Barry J Margulies
Journal:  Viruses       Date:  2021-06-25       Impact factor: 5.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.